Citizens Maintains Market Outperform on Opus Genetics, Lowers Price Target to $11

Benzinga Newsdesk www.benzinga.com Negative 94.7%

Neg 94.7% Neu 0% Pos 0%

Citizens analyst Jonathan Wolleben maintains Opus Genetics (NASDAQ:IRD) with a Market Outperform and lowers the price target from $12 to $11.